Medication Regimen for Acute Ischemic Stroke
Continue aspirin 325 mg daily and add clopidogrel 75 mg daily for 90 days, then transition to long-term aspirin monotherapy, while initiating high-intensity statin therapy and optimizing blood pressure control.
Acute Antiplatelet Management
Given the acute right frontal and putamen infarcts with documented aspirin responsiveness, dual antiplatelet therapy (DAPT) is indicated for stroke prevention in the acute phase 1. The evidence supports:
- Aspirin 325 mg daily as the foundation of therapy 2
- Add clopidogrel 75 mg daily for up to 90 days to reduce early recurrent stroke risk 1
The 2013 AHA/ASA guidelines demonstrate that early initiation of aspirin within 48 hours of stroke provides modest but statistically significant benefit, primarily through prevention of recurrent events 1. While the FASTER pilot trial showed clopidogrel reduced 90-day stroke risk from 10.8% to 7.1% (though with 2 intracranial hemorrhages versus none in placebo), the benefit in preventing recurrent stroke outweighs hemorrhagic risk in this acute setting 1.
Long-Term Secondary Prevention
After 90 days of DAPT, transition to aspirin 325 mg daily as monotherapy for long-term stroke prevention 2. The 2022 AAN practice advisory specifically recommends aspirin 325 mg/d for long-term prevention of stroke and death in patients with symptomatic intracranial atherosclerotic disease 2.
Critical Adjunctive Therapies
Beyond antiplatelet agents, aggressive risk factor modification is essential:
- High-intensity statin therapy targeting LDL cholesterol <70 mg/dL 2
- Blood pressure control with target <140/90 mm Hg 2
- At least moderate physical activity 2
- Treatment of other modifiable vascular risk factors 2
Important Caveats Regarding the Left ICA Aneurysm
The presence of a left internal carotid artery aneurysm requires careful consideration but should not alter the acute stroke management. Key points:
- The acute infarcts are in the right hemisphere (frontal cortex and putamen), while the aneurysm is on the left side—these are separate pathologies
- Aspirin has been found safe in patients harboring cerebral aneurysms and may actually decrease rupture rates through COX-2 inhibition 3
- The aneurysm requires separate neurosurgical/neurointerventional evaluation for treatment planning, but this does not contraindicate necessary stroke prevention therapy
Anticoagulation Considerations
Do not initiate anticoagulation despite the presence of acute stroke 1. The 2013 AHA/ASA guidelines explicitly state that urgent anticoagulation with the goal of preventing early recurrent stroke or halting neurological worsening is not recommended (Class III; Level of Evidence A) 1. This is particularly important given:
- Increased risk of hemorrhagic transformation in moderate-to-severe strokes 1
- No evidence that anticoagulation improves outcomes in acute ischemic stroke 1
- The presence of an unruptured aneurysm further increases hemorrhagic risk
Monitoring Strategy
Given the documented aspirin responsiveness (platelet response assay showing aspirin effect), continue monitoring for:
- Clinical signs of recurrent stroke or TIA
- Bleeding complications (though hemorrhagic events with standard DAPT are relatively low at 1.8% in stroke patients) 4
- Blood pressure and lipid control
- Aneurysm stability through appropriate imaging follow-up
The combination of DAPT for 90 days followed by long-term aspirin monotherapy, coupled with aggressive risk factor modification, provides the best evidence-based approach to reduce mortality and recurrent stroke risk while maintaining acceptable bleeding risk in this complex patient 1, 2.